| Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis AJ Sanyal, N Chalasani, KV Kowdley, A McCullough, AM Diehl, NM Bass, ... New England Journal of Medicine 362 (18), 1675-1685, 2010 | 3880 | 2010 |
| Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial BA Neuschwander-Tetri, R Loomba, AJ Sanyal, JE Lavine, ML Van Natta, ... The Lancet 385 (9972), 956-965, 2015 | 2510 | 2015 |
| A multisociety Delphi consensus statement on new fatty liver disease nomenclature ME Rinella, JV Lazarus, V Ratziu, SM Francque, AJ Sanyal, F Kanwal, ... Hepatology 78 (6), 1966-1986, 2023 | 2450 | 2023 |
| Sofosbuvir for previously untreated chronic hepatitis C infection E Lawitz, A Mangia, D Wyles, M Rodriguez-Torres, T Hassanein, ... New England Journal of Medicine 368 (20), 1878-1887, 2013 | 2450 | 2013 |
| Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis KV Kowdley, SC Gordon, KR Reddy, L Rossaro, DE Bernstein, E Lawitz, ... New England Journal of Medicine 370 (20), 1879-1888, 2014 | 1519 | 2014 |
| Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options IM Jacobson, SC Gordon, KV Kowdley, EM Yoshida, M Rodriguez-Torres, ... New England journal of medicine 368 (20), 1867-1877, 2013 | 1439 | 2013 |
| ABT-450/r–ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis F Poordad, C Hezode, R Trinh, KV Kowdley, S Zeuzem, K Agarwal, ... New England Journal of Medicine 370 (21), 1973-1982, 2014 | 1197 | 2014 |
| A placebo-controlled trial of obeticholic acid in primary biliary cholangitis F Nevens, P Andreone, G Mazzella, SI Strasser, C Bowlus, P Invernizzi, ... New England Journal of Medicine 375 (7), 631-643, 2016 | 1171 | 2016 |
| Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial ZM Younossi, V Ratziu, R Loomba, M Rinella, QM Anstee, Z Goodman, ... The Lancet 394 (10215), 2184-2196, 2019 | 1164 | 2019 |
| Treatment of HCV with ABT-450/r–ombitasvir and dasabuvir with ribavirin JJ Feld, KV Kowdley, E Coakley, S Sigal, DR Nelson, D Crawford, ... New England Journal of Medicine 370 (17), 1594-1603, 2014 | 1137 | 2014 |
| Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial KD Lindor, KV Kowdley, EJ Heathcote, ME Harrison, R Jorgensen, ... Hepatology 39 (3), 770-778, 2004 | 1032 | 2004 |
| Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease M Charlton, GT Everson, SL Flamm, P Kumar, C Landis, RS Brown Jr, ... Gastroenterology 149 (3), 649-659, 2015 | 963 | 2015 |
| Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases BR Bacon, PC Adams, KV Kowdley, LW Powell, AS Tavill Hepatology 54 (1), 328-343, 2011 | 931* | 2011 |
| Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B MG Peters, HW Hann, P Martin, EJ Heathcote, P Buggisch, R Rubin, ... Gastroenterology 126 (1), 91-101, 2004 | 915 | 2004 |
| All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III study DR Nelson, JN Cooper, JP Lalezari, E Lawitz, PJ Pockros, N Gitlin, ... Hepatology 61 (4), 1127-1135, 2015 | 908 | 2015 |
| Global epidemiology of hepatitis B virus B Custer, SD Sullivan, TK Hazlet, U Iloeje, DL Veenstra, KV Kowdley Journal of clinical gastroenterology 38 (10), S158-S168, 2004 | 872 | 2004 |
| Endpoints and clinical trial design for nonalcoholic steatohepatitis AJ Sanyal, EM Brunt, DE Kleiner, KV Kowdley, N Chalasani, JE Lavine, ... Hepatology 54 (1), 344-353, 2011 | 867 | 2011 |
| High‐dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis KD Lindor, KV Kowdley, VAC Luketic, ME Harrison, T McCashland, ... Hepatology 50 (3), 808-814, 2009 | 862 | 2009 |
| A randomized, placebo‐controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis SL Friedman, V Ratziu, SA Harrison, MF Abdelmalek, GP Aithal, ... Hepatology 67 (5), 1754-1767, 2018 | 734 | 2018 |
| Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid GM Hirschfield, A Mason, V Luketic, K Lindor, SC Gordon, M Mayo, ... Gastroenterology 148 (4), 751-761. e8, 2015 | 700 | 2015 |